American Century Companies Inc. Purchases 17,666 Shares of Atea Pharmaceuticals, Inc. $AVIR

American Century Companies Inc. lifted its position in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) by 12.2% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 162,861 shares of the company’s stock after buying an additional 17,666 shares during the quarter. American Century Companies Inc. owned about 0.19% of Atea Pharmaceuticals worth $487,000 as of its most recent filing with the SEC.

Other large investors also recently added to or reduced their stakes in the company. Russell Investments Group Ltd. boosted its holdings in Atea Pharmaceuticals by 10,793.3% in the first quarter. Russell Investments Group Ltd. now owns 54,902 shares of the company’s stock worth $164,000 after purchasing an additional 54,398 shares in the last quarter. HighTower Advisors LLC increased its holdings in shares of Atea Pharmaceuticals by 49.9% during the 1st quarter. HighTower Advisors LLC now owns 75,088 shares of the company’s stock valued at $225,000 after acquiring an additional 25,001 shares during the last quarter. Nuveen LLC acquired a new position in shares of Atea Pharmaceuticals during the 1st quarter valued at about $870,000. Deutsche Bank AG acquired a new position in shares of Atea Pharmaceuticals during the 1st quarter valued at about $180,000. Finally, CM Management LLC grew its holdings in Atea Pharmaceuticals by 66.7% during the first quarter. CM Management LLC now owns 500,000 shares of the company’s stock valued at $1,495,000 after purchasing an additional 200,000 shares during the last quarter. 86.67% of the stock is owned by institutional investors.

Atea Pharmaceuticals Price Performance

AVIR stock opened at $3.37 on Friday. The company has a 50-day moving average of $3.56 and a two-hundred day moving average of $3.19. Atea Pharmaceuticals, Inc. has a 52-week low of $2.45 and a 52-week high of $4.14. The stock has a market capitalization of $267.44 million, a price-to-earnings ratio of -2.09 and a beta of 0.24.

Atea Pharmaceuticals (NASDAQ:AVIR) last announced its earnings results on Thursday, August 7th. The company reported ($0.44) earnings per share for the quarter, beating the consensus estimate of ($0.46) by $0.02. Equities analysts expect that Atea Pharmaceuticals, Inc. will post -2.01 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen downgraded Atea Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, August 9th. One analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $6.00.

Atea Pharmaceuticals Profile

Atea Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19.